Wiley Bros. Aintree Capital, LLC Biogen Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $8.04 Billion
- Q4 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 1,721 shares of BIIB stock, worth $236,344. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,721
Previous 2,196
21.63%
Holding current value
$236,344
Previous $425,000
38.12%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BIIB
# of Institutions
996Shares Held
130MCall Options Held
1.57MPut Options Held
2.25M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.3 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.2 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$1.02 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$677 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $19.8B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...